Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MDS 2024 | Preclinical studies of tasquinimod in MDS: in vitro and in vivo investigations

Both inflammatory activation and dysregulation of the immune response in the bone marrow niche are key players in the pathogenesis of myelodysplastic syndromes (MDS). Manja Wobus, PhD, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the findings of preclinical studies investigating tasquinimod, a small molecular oral inhibitor of S100A9, for mitigating the effects of the pathological inflammasome activation in the bone microenvironment seen in MDS. The agent was studied in vitro in mesenchymal stromal cells (MSCs) and in vivo in transgenic murine models. Dr Wobus highlights that the findings provide the first evidence that tasquinimod may have potential benefits for cytopenic patients with lower-risk MDS. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research Funding: Active Biotech.